Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Birgit Grund is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Extended follow-up of randomized participants in the INSIGHT START trial
Grund, B. & Neaton, J.
NIH Nat'l Inst of Allergy & Infect Dis
5/17/19 → 4/30/25
Project: Research project
-
Mathematical Sciences: Smoothed Nonparametric Hazard Regression
7/1/95 → 6/30/99
Project: Research project
-
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19
for the ACTIV-3/TICO Study Group, Mar 15 2024, In: Journal of Infectious Diseases. 229, 3, p. 671-679 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV
Murray, D. D., Grund, B., Macpherson, C. R., Ekenberg, C., Zucco, A. G., Reekie, J., Dominguez-Dominguez, L., Leung, P., Fusco, D., Gras, J., Gerstoft, J., Helleberg, M., Borges, Á. H., Polizzotto, M. N. & Lundgren, J. D., Mar 1 2023, In: AIDS. 37, 3, p. 379-387 9 p.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial
ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group, Sep 2023, In: The Lancet Respiratory Medicine. 11, 9, p. 791-803 13 p.Research output: Contribution to journal › Article › peer-review
Open Access4 Scopus citations -
Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)
Murray, D. D., Babiker, A. G., Baker, J. V., Barkauskas, C. E., Brown, S. M., Chang, C. C., Davey, V. J., Gelijns, A. C., Ginde, A. A., Grund, B., Higgs, E., Hudson, F., Kan, V. L., Lane, H. C., Murray, T. A., Paredes, R., Parmar, M. K. B., Pett, S., Phillips, A. N., Polizzotto, M. N., & 8 others , Feb 2022, In: Clinical Trials. 19, 1, p. 52-61 10 p.Research output: Contribution to journal › Article › peer-review
Open Access14 Scopus citations -
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group, May 2022, In: The Lancet Infectious Diseases. 22, 5, p. 622-635 14 p.Research output: Contribution to journal › Article › peer-review
Open Access132 Scopus citations